title: Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.
abstract: One hundred and sixteen Latin American type 2 diabetic patients previously only on a diet were enrolled in this multicenter, multinational, nonrandomized, noncontrolled study. Only 109 completed the study. After 8 weeks of treatment with 120 mg of nateglinide, administered prior to each meal, the postprandial (2 h) glucose concentration decreased to 85.11 +/- 5.65 mg/dl (p < 0.0001), and HbA(1c) values decreased to 1.06 +/- 0.10% (p < 0.0001). No response differences were detected in relation to age, gender, or ethnicity, but we did encounter a better response in recently diagnosed patients (<or=1 year). No serious adverse events were observed. We can, therefore, conclude that nateglinide is a well-tolerated, safe, and effective insulinotropic agent.
authors.affiliation: Research Unit in Metabolic Diseases, Centro Médico Nacional, Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. sislasa@att.net.mx
authors.forename: Sergio
authors.initials: S
authors.lastname: Islas-Andrade
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Revilla-Monsalve
authors.forename: Evelyn
authors.initials: E
authors.lastname: Martínez de Hurtado
authors.forename: Luis F
authors.initials: LF
authors.lastname: Chacín
authors.forename: Quenemari R
authors.initials: QR
authors.lastname: Caminos
authors.forename: Hernán
authors.initials: H
authors.lastname: Yupanqui
authors.forename: Gloria
authors.initials: G
authors.lastname: López
authors.forename: Walter
authors.initials: W
authors.lastname: de la Torre
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000209:etiology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007843:Latin America; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019518:Postprandial Period / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine